Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Abbott (ABT) Gains in Core Diagnostics With FDA Nod for Alinity H

Abbott's (ABT) Alinity h-series not only delivers technological innovation but also addresses the realistic challenges faced by modern healthcare systems.

Abbott (ABT) EPD Arm Grows, Low Testing Sales Play Spoilsport

Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

Investors are optimistic about Abbott (ABT) on its strategic expansion in the global market and recovery within the Nutrition segment.

Asensus Surgical (ASXC) Q2 Loss Widens, Revenues In Line

Asensus Surgical (ASXC) reports a significant increase in total surgical procedures completed utilizing the Senhance System.

National Vision (EYE) Q2 Earnings Top Estimates, Margins Down

National Vision's (EYE) second-quarter 2023 performance highlights positive comparable store sales growth, retention and recruitment trends.

The Zacks Analyst Blog Highlights JPMorgan Chase, Salesforce, Abbott Laboratories, HCA Healthcare and General Motors

JPMorgan Chase, Salesforce, Abbott Laboratories, HCA Healthcare and General Motors are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for JPMorgan Chase, Salesforce & Abbott Laboratories

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Salesforce, Inc. (CRM) and Abbott Laboratories (ABT).

Charles River (CRL) Q2 Earnings Top, 2023 View Narrowed

Charles River (CRL) registers robust growth in small research models, research model services and the Safety Assessment business.

Insulet (PODD) Q2 Earnings Beat, Sales Growth View Raised

Insulet's (PODD) Omnipod 5 gains market share in the second quarter within the diabetes technology market as the only FDA-approved fully disposable, pod-based automated insulin delivery system.

QIAGEN (QGEN) Q2 Earnings and Revenues Top, '23 View Slashed

QIAGEN (QGEN) surpasses the earnings and revenue outlook in the second quarter of 2023 amid a challenging macro environment.

SmileDirectClub (SDC) Q2 Earnings Miss Estimates, '23 View Up

SmileDirectClub (SDC) reports a higher-than-expected loss in the second quarter of 2023.

Henry Schein (HSIC) Q2 Earnings Top, Operating Margin Dips

Henry Schein's (HSIC) second quarter 2023 performance demonstrates strength in the North American dental business.

Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip

According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies.

ResMed's (RMD) Q4 Earnings Miss, Revenues Beat Estimates

ResMed (RMD) records a robust sales performance in fiscal Q4 backed by the ongoing combined availability of cloud-connected AirSense 10 and AirSense 11 sleep devices.

Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View

Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business.

Stryker (SYK) Q2 Earnings Beat Estimates, Volume Improves

Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.

Inari Medical (NARI) Q2 Earnings Top, Revenues Rise Y/Y

Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.

Cigna (CI) Q2 Earnings Beat on Strong U.S. Commercial Unit

Cigna's (CI) Q2 results reflect solid premium rate hikes and a growing membership base across its U.S. Commercial and Medicare Advantage businesses.

PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View

PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.

Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up

Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues.

BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.

Envista (NVST) Q2 Earnings Top Estimates, Margins Expands

Consistent growth in the Specialty Products & Technologies segment and a return to growth in the Equipment & Consumables segment drive Envista's (NVST) Q2 revenues.

Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.

STERIS (STE) Q1 Earnings Beat Estimates, Gross Margin Falls

Barring Life Sciences and Dental, rest of STERIS (STE) operating segments report organic revenue growth in fiscal Q1.

McKesson (MCK) Q1 Earnings Beat Estimates, U.S. Sales Strong

McKesson's (MCK) fiscal first-quarter 2024 results benefit from growth in the United States. Divestment hurts the International segment.